Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Precision BioSciences Inc. on December 14, 2020, covering events reported as of December 8, 2020. The filing addresses significant changes in the Company's executive leadership regarding its financial officers.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statement data.
Material Changes
- Resignation of CFO: Abid Ansari notified the Company of his resignation as Chief Financial Officer, effective January 1, 2021. Upon departure, he will cease serving as the principal financial officer and principal accounting officer.
- Appointment of Interim CFO: On December 11, 2020, the Board appointed Alex Kelly, previously the Chief Corporate Affairs Officer, as Interim Chief Financial Officer, effective upon Mr. Ansari's departure.
- Appointment of Interim Principal Accounting Officer: On December 11, 2020, the Board appointed Shane Barton, Vice President and Corporate Controller, as the interim principal accounting officer.
Management Commentary and Background
Mr. Kelly, age 54, joined the Company in October 2020 from Allergan plc, where he served as Executive Vice President, Corporate Affairs. His background includes leadership roles at Actavis, Forest Labs, Bausch + Lomb, Merck, and Novartis. Mr. Barton, age 50, has served as Vice President and Corporate Controller since May 2020 and previously held similar roles at Vivelix Pharmaceuticals and Cempra Pharmaceuticals. Both appointees are expected to enter into the Company's standard indemnification agreement.
Key Facts for Investor Verification
- Confirm the effective date of the CFO transition (January 1, 2021).
- Verify the professional backgrounds and prior roles of the new Interim CFO (Alex Kelly) and Interim Principal Accounting Officer (Shane Barton).
- Monitor subsequent filings for the appointment of a permanent Chief Financial Officer.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.